PAVmed (NASDAQ:PAVM) Upgraded by Wall Street Zen to Sell Rating

Wall Street Zen upgraded shares of PAVmed (NASDAQ:PAVM) to a sell rating in a research report report published on Saturday.

Several other equities research analysts also recently commented on the company. Zacks Research downgraded PAVmed from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. Weiss Ratings restated a “sell (d)” rating on shares of PAVmed in a research note on Thursday, January 22nd. Finally, Ascendiant Capital Markets cut their target price on shares of PAVmed from $600.00 to $510.00 and set a “buy” rating for the company in a research note on Wednesday, December 10th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, PAVmed has a consensus rating of “Hold” and a consensus target price of $510.00.

PAVmed Trading Up 1.7%

Shares of PAVM stock opened at $10.45 on Friday. The firm’s fifty day moving average price is $8.97 and its two-hundred day moving average price is $11.57. PAVmed has a 1 year low of $6.00 and a 1 year high of $28.44. The firm has a market capitalization of $10.24 million, a P/E ratio of -0.61 and a beta of 1.12.

Institutional Trading of PAVmed

A hedge fund recently raised its stake in PAVmed stock. Jane Street Group LLC raised its position in PAVmed Inc. (NASDAQ:PAVM) by 392.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,676 shares of the company’s stock after buying an additional 41,990 shares during the quarter. Jane Street Group LLC owned 0.31% of PAVmed worth $32,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 19.93% of the company’s stock.

About PAVmed

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.